Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xilio Therapeutics
Biotech
AbbVie pays Xilio $52M upfront in latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality.
James Waldron
Feb 12, 2025 8:29am
FDA's principal deputy to depart agency—Chutes & Ladders
Dec 20, 2024 8:30am
Gilead pays $43.5M for Xilio's early-phase IL-12 prospect
Mar 28, 2024 8:08am
Illumina nets new CEO—Chutes & Ladders
Sep 8, 2023 9:30am
Drugs up for sale, on the shelf in biotech pipeline clear-outs
Nov 9, 2022 9:40am
Xilio inks Merck deal to run checkpoint inhibitor combo trial
May 25, 2021 8:55am
